Gilead's $5B Tubulis Deal Intensifies ADC Competition with Pfizer
Gilead Sciences agreed to acquire Tubulis GmbH for up to $5 billion, comprising $3.15 billion upfront and $1.85 billion in milestone payments, to expand its antibody-drug conjugate pipeline. This move heightens competition with Pfizer after its $43 billion Seagen acquisition and could pressure Pfizer’s ADC market share.
1. Deal Overview
Gilead Sciences will acquire Germany-based Tubulis GmbH for $3.15 billion in upfront cash plus up to $1.85 billion in development and regulatory milestones. Tubulis brings a proprietary ADC platform and clinical programs targeting ovarian and lung cancers, with planned integration into Gilead’s existing ADC research arm based in Munich.
2. Impact on Pfizer
The deal intensifies competition in the ADC space where Pfizer bolstered its position with a $43 billion Seagen acquisition in 2023. Investors will watch for potential shifts in market share, R&D prioritization and pricing dynamics as Gilead and Pfizer vie for leadership in antibody-drug conjugate therapies.